Biosimilars
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,015
NCT04115488
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
Phase: Phase 3
Role: Lead Sponsor
Start: Oct 1, 2019
Completion: Feb 7, 2022
NCT05771155
Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio®
Start: Jul 24, 2023
Completion: Sep 30, 2025
Loading map...